You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 2, February 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Ophthalmology
 •Dry Eye Syndromes
 •Ophthalmological Disorders, Other
 •Dermatologic Disorders
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Risk Factors for the Development of Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Julie Gueudry, MD; Jean-Claude Roujeau, MD; Michel Binaghi, MD; Gisèle Soubrane, MD, PhD; Marc Muraine, MD, PhD

Arch Dermatol. 2009;145(2):157-162.

Objectives  To describe the acute and late ocular manifestations of toxic epidermal necrosis (TEN), Stevens-Johnson syndrome (SJS), and overlap syndrome and to identify predictors for the development of ocular complications.

Design  Retrospective cohort study.

Setting  A single referral unit in a university hospital.

Patients  The study included 159 patients (mean [SD] age, 49.9 [19.8] years) with TEN and SJS during an 8-year period. Forty-nine patients were contacted at least 15 months after hospital discharge.

Main Outcome Measures  Records were reviewed for demographics, cause of the condition, and severity of ocular involvement. The patients were contacted to assess late ocular complications.

Results  A total of 117 patients (74%) had acute ocular involvement, which was mild in 58%, moderate in 8%, and severe in 8%. Patients with TEN had more frequent (odds ratio [OR], 2.7; 95% confidence interval [CI], 1.06-6.90; P = .05) but not more severe (OR, 0.95; 95% CI, 0.20-4.5; P = .99) acute ocular involvement. Forty-nine patients were contacted at least 15 months after hospital discharge, and 63% had late ocular complications. Dry eye syndrome was the most common. The mean (SD) Ocular Surface Disease Index score was 32.9 (30.3) (range, 0-97.5). The severity of the acute ocular disease was found to be the only significant risk factor of late complications (P = .002), even though 5 patients without acute ocular involvement developed dry eye syndrome.

Conclusions  Ocular involvement is common in patients with SJS and TEN. Late complications are more frequent in patients with severe initial eye involvement but may also develop in patients without patent initial ocular symptoms.


Author Affiliations: Department of Ophthalmology, Hôpital Charles Nicolle, Rouen, France (Drs Gueudry and Muraine); and Departments of Dermatology (Dr Roujeau) and Ophthalmology (Drs Binaghi and Soubrane), Hôpital Henri Mondor, Créteil, France.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Dermatology
Arch Dermatol. 2009;145(2):119.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Management of Severe Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Sotozono et al.
Arch Dermatol 2009;145:1336-1337.
FULL TEXT  

The Management of Severe Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis--Reply
Gueudry et al.
Arch Dermatol 2009;145:1337-1338.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.